Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Lifted to Strong-Buy by Zacks Research

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.

Several other brokerages have also recently issued reports on ZLDPF. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

ZLDPF opened at $34.87 on Monday. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $2.49 billion, a PE ratio of 5.78 and a beta of 0.95. Zealand Pharma A/S has a 52 week low of $34.87 and a 52 week high of $83.12. The firm has a 50-day simple moving average of $45.33 and a two-hundred day simple moving average of $46.13.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.